Valeris Taps Syndax Veteran Crowther as CRO to Drive Revenue Growth
Event summary
- Jeff Crowther joins Valeris as Chief Revenue Officer on September 15, 2026, reporting to Chief Commercial Officer Scott Filosi.
- Crowther brings 30+ years of commercial leadership experience in oncology, hematology, CNS, gastroenterology, and infectious diseases.
- Previously built commercial functions at Syndax Pharmaceuticals and SK Life Science, including the successful XCOPRI launch during COVID-19.
- Valeris supports over 500 life sciences customers and has aided millions of patients with access and affordability.
The big picture
Valeris' appointment of Jeff Crowther as CRO underscores its commitment to growth and innovation in the life sciences commercialization space. The move comes as biotech companies increasingly seek integrated partners to navigate complex market access and patient support challenges. With over 500 clients and millions of patients supported, Valeris is positioning itself as a key player in an industry where commercial strategy and patient outcomes are increasingly intertwined.
What we're watching
- Revenue Strategy
- How Crowther's experience in building commercial organizations will translate into scalable revenue growth for Valeris.
- Market Pressure
- Whether Valeris can maintain its patient-centric approach while scaling commercial operations under market pressures.
- Industry Trends
- The pace at which Valeris can become an indispensable partner to life sciences companies amid evolving commercialization needs.
Related topics